Generic Name: talazoparib
Brand Name: Talzenna
Manufacturer: Pfizer Canada Inc.
Therapeutic Area: Breast cancer
Indications: Monotherapy for the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curative radiation or surgery) or metastatic breast cancer, who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting, unless patients were inappropriate for these treatments.
Submission Type: Non-submission
Project Status: Not filed
Recommendation Type: CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer